A phase I/II, dual-center, open-label trial of the safety and efficacy of Tarceva (erlotinib hydrochloride) plus sirolimus in patients with recurrent malignant glioma not on P450-inducing anti-epileptics
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Erlotinib (Primary) ; Sirolimus (Primary)
- Indications Glioma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2016 Study phase changed from phase I/II to phase I, as phase II of the study was not conducted, as reported by ClinicalTrials.gov.
- 27 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.